Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis

• Sponsor: Assiut University (Other)
• Overall Status: Unknown status
• CT.gov ID: NCT03740685
• Collaborator: (none)
• Enrollment: 80
• Location: 1
• Anticipated Duration (Months): 10.9
• Patients Per Site Per Month: 7.3

Study Details

Study Description

Brief Summary

changes in high sensitive C reactive protien with different treatment modalities in acute pancreatitis

Condition or Disease	Intervention/Treatment	Phase
Pancreatitis, Acute	Diagnostic Test: High sesitive C reactive protien

Study Design

• Study Type: Observational
• Anticipated Enrollment: 80 participants
• Observational Model: Cohort
• Time Perspective: Cross-Sectional
• Official Title: Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis
• Anticipated Study Start Date: Nov 9, 2018
• Anticipated Primary Completion Date: Nov 9, 2018
• Anticipated Study Completion Date: Oct 8, 2019

Arms and Interventions

Arm	Intervention/Treatment
Patients with acute pancreatitis All patients will recive different lines of treatment {saline,antibiotics,dexamethasone}	Diagnostic Test: High sesitive C reactive protien; High sesitive C reactive protien will be evaluated at admission time and after 36 hours

Outcome Measures

Primary Outcome Measures

1. High sesitive C reactive protien [72hours]

   Level of High sesitive C reactive protien expected to be changed with different lines of treatment and will be compaered

2. Serum Amylase [72hours]

   Level of Serum Amylase expected to be changed with different lines of treatment and will be compaered

3. Serum Lipase [72hours]

   Level of Serum Lipase expected to be changed with different lines of treatment and will be compaered

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Age>=18 years

• Diagnosis of acute pancreatitis confirmed by at least 2 of the following:

1. Typical epigastric abdominal pain

2. Elevation amylase/lipase >3 times upper limit normal and/or

3. Confirmatory findings on cross-sectional imaging

4. Enrollment within 8 hours of presentation

Exclusion Criteria:

• Class II or greater NYHA heart failure

• Oxygen dependent COPD

• Chronic kidney disease>stage 2

• Existing necrosis on abdominal CT

• Organ dysfunction prior to enrollment

• Sepsis

• Acute respiratory distress syndrome

• Malignancy not in remission for at least 5 years

• Active drug use

• Known allergy to dexamethasone

• Altered mental status

• Insulin-requiring diabetes

• Abdominal surgery within 60days

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Assiut University	Assuit		Egypt	171516

Sponsors and Collaborators

• Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Mahmoud Abdelhamed, principal investigator, Assiut University
• ClinicalTrials.gov Identifier: NCT03740685
• Other Study ID Numbers: CHCPWDTM
• First Posted: Nov 14, 2018
• Last Update Posted: Nov 14, 2018
• Last Verified: Nov 1, 2018

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Pancreatitis

Study Results

No Results Posted as of Nov 14, 2018